I believe the likely non-approval of Orathecin is ALREADY in the stock price and that the stock will soon spike upward as soon as we get the "news". After this news, the ONLY topic to then contemplate will be Dacogen, which IS likely to be approved. In short, today was a great sale day.
Well, if you truly believe something you should stick to your gut. However, I think that there is reason to believe that an orathecin rejection would result in a significant drop in price. Probably $2 or more. They are still at a $300 MM market cap, which is too high without Orathecin and dacogen still somewhat of a question mark to impact revenue in 2005.
if its disapproved. I hope your right then I can pick up the additional 00,000 shares. And I'm serious. I think that's what the mm's are hoping so they can buy back all those shares. Will you be around come June-July. Well you maybe right on the orthecin however you maybe wrong on the outcome during a 6 month period.